Identification of 2-[2-(4-tert-butylphenyl)ethyl]-N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide (29) as an orally available MGAT2 inhibitor

Add time:07/12/2019    Source:sciencedirect.com

MGAT2 (monoacylglycerol acyltransferase 2) is expected to be an attractive target for the drug treatment of obesity, diabetes, and other disease. We describe our exploration and structure–activity relationship (SAR) study of 2,3-dihydro-1H-isoindole-5-sulfonamide derivatives. In this study, we identified 29 as an orally available inhibitor of MGAT2 through optimization especially in terms of solubility. This compound exhibited moderate potency in the enzyme inhibitory assay (IC50 = 1522 nM) and significant suppression of fat absorption (57% inhibition) in mice oral lipid tolerance test.

We also recommend Trading Suppliers and Manufacturers of 5-chloro-1-(3-diMethylaMinopropyl)-1-(4-fluorophenyl)-phthalan (cas 64169-45-5). Pls Click Website Link as below: cas 64169-45-5 suppliers

Prev:Glycine, a new regulator of glutamine metabolism in isolated rat-liver cells
Next:Tungsten carbide/carbon composites coated with little platinum nano particles derived from the redox reaction between in-situ synthesized WC1−x and Chloroplatinic Acid (cas 143337-19-3) as the electrocatalyst for hydrogen evolution reaction)